Adam Pulaski of Pulaski Law Firm, PLLC has been appointed as co-lead counsel in Zantac multidistrict litigation in which hundreds of federally filed lawsuits have been consolidated in the Southern District of Florida. Out of all the attorneys who applied for leadership positions in the Zantac injury multidistrict litigation, only four were chosen. In making the decision, the Court has considered many factors, including the individual applicant’s skill, experience, background, ethical standards, professionalism, collaboration, other leadership positions, and reputation earned from colleagues and judges in other litigation.
Adam was appointed to this leadership position to help build and manage the nationwide product liability litigation. The lawsuits filed allege that the companies that made and sold Zantac knew its active ingredient, ranitidine, metabolized in the human body to form a carcinogen known as N-nitrosodimethylamine, or NDMA.
Across the country, patients and consumers who were prescribed the popular heartburn medication or who purchased the product over-the-counter have been affected and scores have suffered injury, including being diagnosed with specific cancers of the digestive system. The contamination concerns are so serious that the U.S. Food and Drug Administration announced it was pulling all prescription and over-the-counter Zantac from the market.
Hundreds of personal injury and class action claims have already been filed and experts say the number of claims is expected to continue to mount over the coming months. Our attorneys are working to ensure that Zantac patients and consumers around the country get the compensation they need and the justice they deserve.
